PRECISE-DAPT Score
Estimates out-of-hospital bleeding risk in patients treated with dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).
Advice
- Use the PRECISE-DAPT Score to add additional information to individualize DAPT duration after PCI by identifying patients at high bleeding risk (score ≥ 25) who may benefit from shorter therapy.
- Always interpret the result in context with the patient’s ischemic risk, comorbidities, and frailty. Avoid rigid cutoffs; instead, use the score to help weigh shared decision-making on DAPT duration, especially in borderline or elderly patients where bleeding risk often outweighs ischemic benefit.
- Additional risk scores for bleeding prediction such as PRECISE-HBR or ARC-HBR also exist and may be worth comparing PRECISE-DAPT with (link 1, link 2). The 2025 ACC/AHA guidelines for management of Acute Coronary Syndromes recommend considering the ARC-HBR score.
Management
- For patients with a PRECISE-DAPT score ≥25, consider short DAPT (3–6 months) if ischemic risk is low or bleeding risk is a concern, then transition to single antiplatelet therapy.
- For patients with a score <25, standard or extended DAPT may be reasonable, particularly if ischemic risk is high.
- Always individualize duration based on bleeding vs. ischemic risk, stent type, and presentation—some lower-bleeding-risk patients may still benefit from longer DAPT.
Critical Actions
- Reassess regularly if renal function, hemoglobin, or clinical status changes.
- Address reversible bleeding risks (e.g., treat anemia, discontinue unnecessary antithrombotics).
- Engage in shared decision-making with the patient, discussing the trade-off between bleeding and ischemic risk.
- Avoid over-reliance on the calculator in patients outside the derivation cohort (e.g., triple therapy).